📊 BCYC Key Takeaways
Investment Thesis
Bicycle Therapeutics is a pre-commercial pharmaceutical company with strong cash position ($628.1M) supporting runway, but demonstrates severe unprofitability with -$252.0M free cash flow burn and -301.7% net margin. While 105.8% revenue growth is encouraging, the company is consuming cash rapidly with operating losses of -$247.1M, raising questions about path to profitability and capital efficiency.
BCYC Strengths
- Exceptional liquidity with $628.1M cash and 11.98x current ratio providing substantial runway
- Strong revenue growth of 105.8% YoY demonstrating commercial traction
- Minimal leverage with 0.05x debt-to-equity ratio and only $30.9M long-term debt
- 16 Form 4 insider filings in last 90 days suggest active management engagement
BCYC Risks
- Massive cash burn of $252.0M FCF with -347.2% FCF margin indicating unsustainable trajectory
- Operating losses of -$247.1M far exceed revenue generation, showing negative unit economics
- Negative interest coverage of -300.9x means company cannot service debt from operations
- Revenue growth insufficient to offset operating losses; burn rate suggests 2-3 years of cash runway at current pace
- Typical biotech R&D model with high upfront costs, but sustained -$249.7M operating cash burn indicates commercialization challenges
Key Metrics to Watch
- Operating cash flow trend and path to cash flow breakeven
- Revenue growth sustainability and product pipeline advancement
- Operating expense ratio and efficiency improvements quarter-over-quarter
- Cash runway and burn rate deceleration trajectory
- Gross margin development once reported with higher revenue scale
BCYC Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 11.98x current ratio provides a solid financial cushion.
BCYC Profitability Ratios
BCYC vs Healthcare Sector
How BICYCLE THERAPEUTICS PLC compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
BCYC Balance Sheet & Liquidity
BCYC 5-Year Financial Trend
5-Year Trend Summary: BICYCLE THERAPEUTICS PLC's revenue has grown significantly by 426% over the 5-year period, indicating strong business expansion. The most recent EPS of $-5.08 indicates the company is currently unprofitable.
BCYC Growth Metrics (YoY)
BCYC Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $2.7M | -$26.6M | $-0.74 |
| Q2 2025 | $2.9M | -$26.6M | $-0.77 |
| Q1 2025 | $10.0M | -$26.6M | $-0.62 |
| Q3 2024 | $2.7M | -$26.6M | $-0.74 |
| Q2 2024 | $9.4M | -$26.6M | $-0.77 |
| Q1 2024 | $4.9M | -$26.6M | $-0.62 |
| Q3 2023 | $3.0M | -$26.8M | $-0.96 |
| Q2 2023 | $4.4M | -$26.8M | $-0.90 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
BCYC Capital Allocation
BCYC SEC Filings
Access official SEC EDGAR filings for BICYCLE THERAPEUTICS PLC (CIK: 0001761612)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BCYC
What is the AI rating for BCYC?
BICYCLE THERAPEUTICS PLC (BCYC) has an AI rating of SELL with 85% confidence, based on fundamental analysis of SEC EDGAR filings.
What are BCYC's key strengths?
Exceptional liquidity with $628.1M cash and 11.98x current ratio providing substantial runway. Strong revenue growth of 105.8% YoY demonstrating commercial traction.
What are the risks of investing in BCYC?
Massive cash burn of $252.0M FCF with -347.2% FCF margin indicating unsustainable trajectory. Operating losses of -$247.1M far exceed revenue generation, showing negative unit economics.
What is BCYC's revenue and growth?
BICYCLE THERAPEUTICS PLC reported revenue of $72.6M.
Does BCYC pay dividends?
BICYCLE THERAPEUTICS PLC does not currently pay dividends.
Where can I find BCYC SEC filings?
Official SEC filings for BICYCLE THERAPEUTICS PLC (CIK: 0001761612) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BCYC's EPS?
BICYCLE THERAPEUTICS PLC has a diluted EPS of $-3.16.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.